All In Biotech

Free tool

FAERS Monitor: Elestrin

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

FDA's data service returned an error (500). The numbers below may be missing or incomplete.

Reports naming NDA 021813 or its brand name (Elestrin, Estradiol). Reports on generic versions are filed under their own applications.

Reports

46,961

Serious

0

0% of reports

Hospitalization

7,232

Death reported

909

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

Nothing to show.

Reports by year received

View as table
YearReports
2004524
2005571
2006402
20071,462
2008428
2009599
2010954
2011843
20121,139
2013877
20141,113
20151,917
20162,350
20172,138
20182,487
20192,867
20202,875
20212,829
20223,051
20233,552
20243,700
20255,254
20265,027

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,007,198 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.